Fecal microbiota transplantation in childhood: past, present, and future

Gu, Xu; Chen, Zhaohong; Zhang, Shucheng

doi:10.1007/s12519-022-00655-w

Cited by 9 publications

(3 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fecal microbiota transplantation (FMT) is an effective approach to restoring the diversity and structure of the microbiota by transferring healthy gut microbiota to recipients. Extensive research has been conducted on FMT for various clinical disorders associated with the microbiome, in both adult [ 107 ] and pediatric populations [ 108 ].…”

Section: Microbiota Modulatory Therapies In Ckd Patientsmentioning

confidence: 99%

Exploring a Complex Interplay: Kidney–Gut Axis in Pediatric Chronic Kidney Disease

Mocanu,

Bogos,

Lazaruc

et al. 2023

Nutrients

View full text Add to dashboard Cite

The human intestinal microbiota is a highly intricate structure with a crucial role in promoting health and preventing disease. It consists of diverse microbial communities that inhabit the gut and contribute to essential functions such as food digestion, nutrient synthesis, and immune system development. The composition and function of the gut microbiota are influenced by a variety of factors, including diet, host genetics, and environmental features. In pediatric patients, the gut microbiota is particularly dynamic and vulnerable to disruption from endogenous and exogenous factors. Recent research has focused on understanding the interaction between the gut and kidneys. In individuals with chronic kidney disease, there is often a significant disturbance in the gut microbiota. This imbalance can be attributed to factors like increased levels of harmful toxins from the gut entering the bloodstream, inflammation, and oxidative stress. This review looks at what is known about the link between a child’s gut–kidney axis, how dysbiosis, or an imbalance in the microbiome, affects chronic kidney disease, and what treatments, both pharmaceutical and non-pharmaceutical, are available for this condition.

show abstract

Section: Microbiota Modulatory Therapies In Ckd Patientsmentioning

confidence: 99%

Exploring a Complex Interplay: Kidney–Gut Axis in Pediatric Chronic Kidney Disease

Mocanu,

Bogos,

Lazaruc

et al. 2023

Nutrients

View full text Add to dashboard Cite

show abstract

“…Currently, clostridium difficile infection and recurrent clostridium difficile infection are considered to be the most appropriate indications for FMT in children. Moreover, FMT has also shown promising therapeutic effects in other pediatric diseases, including inflammatory bowel disease, irritable bowel syndrome, functional constipation, non-alcoholic fatty liver disease, ASD and diabetes ( 11 ). Although FMT has shown promise in treating various pediatric conditions, it remains under research and is not yet approved by clinical guidelines.…”

Section: Introductionmentioning

confidence: 99%

Effects and microbiota changes following oral lyophilized fecal microbiota transplantation in children with autism spectrum disorder

Li,

Xiao,

Cao

et al. 2024

Front. Pediatr.

View full text Add to dashboard Cite

Background and purposeAutism spectrum disorder (ASD) is a group of heterogeneous neurodevelopmental disorders that is characterized by core features in social communication impairment and restricted, repetitive sensory-motor behaviors. This study aimed to further investigate the utilization of fecal microbiota transplantation (FMT) in children with ASD, both with and without gastrointestinal (GI) symptoms, evaluate the effect of FMT and analyze the alterations in bacterial and fungal composition within the gut microbiota.MethodsA total of 38 children diagnosed with ASD participated in the study and underwent oral lyophilized FMT treatment. The dosage of the FMT treatment was determined based on a ratio of 1 g of donor stool per 1 kg of recipient body weight, with a frequency of once every 4 weeks for a total of 12 weeks. In addition, 30 healthy controls (HC) were included in the analysis. The clinical efficacy of FMT was evaluated, while the composition of fecal bacteria and fungi was determined using 16S rRNA and ITS gene sequencing methods.ResultsMedian age of the 38 children with ASD was 7 years. Among these children, 84.2% (32 of 38) were boys and 81.6% (31 of 38) exhibited GI symptoms, with indigestion, constipation and diarrhea being the most common symptoms. Sample collections and assessments were conducted at baseline (week 0), post-treatment (week 12) and follow-up (week 20). At the end of the follow-up phase after FMT treatment, the autism behavior checklist (ABC) scores decreased by 23% from baseline, and there was a 10% reduction in scores on the childhood autism rating scale (CARS), a 6% reduction in scores on the social responsiveness scale (SRS) and a 10% reduction in scores on the sleep disturbance scale for children (SDSC). In addition, short-term adverse events observed included vomiting and fever in 2 participants, which were self-limiting and resolved within 24 h, and no long-term adverse events were observed. Although there was no significant difference in alpha and beta diversity in children with ASD before and after FMT therapy, the FMT treatment resulted in alterations in the relative abundances of various bacterial and fungal genera in the samples of ASD patients. Comparisons between children with ASD and healthy controls (HC) revealed statistically significant differences in microbial abundance before and after FMT. Blautia, Sellimonas, Saccharomycopsis and Cystobasidium were more abundant in children with ASD than in HC, while Dorea were less abundant. After FMT treatment, levels of Blautia, Sellimonas, Saccharomycopsis and Cystobasidium decreased, while levels of Dorea increased. Moreover, the increased abundances of Fusicatenibacter, Erysipelotrichaceae_UCG-003, Saccharomyces, Rhodotorula, Cutaneotrichosporon and Zygosaccharomyces were negatively correlated with the scores of ASD core symptoms.ConclusionsOral lyophilized FMT could improve GI and ASD related symptoms, as well as sleep disturbances, and alter the gut bacterial and fungal microbiota composition in children with ASD.Clinical Trial RegistrationChinese Clinical Trial Registry, ChiCTR2200055943. Registered 28 January 2022, www.chictr.org.cn.

show abstract

“…A review in the Special Issue [14] showed that certain prebiotic-rich diets, such as resveratrol and garlic oil, have demonstrated protective efficacy against CKD in children [15]. In addition, fecal microbiota transplantation [16] and colon dialysis [17] have been shown to be effective in restoring the diversity and structure of intestinal microbiota in children with kidney disease.…”

mentioning

confidence: 99%